Clinical trial · Interventional
Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
Phase I Investigator-initiated Clinical Trial in Patients With Differentiated Thyroid Cancer (Papillary Cancer, Follicular Cancer) by the Targeted Alpha Therapy Drug TAH-1005 ([211At] NaAt) (Alpha-T1 Study)
NCT05275946CI-TRIAL-00088888completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Single intravenous administration of TAH-1005 is performed in patients with differentiated thyroid cancer (papillary cancer, follicular cancer) who cannot obtain therapeutic effect with standard treatment or who have difficulty in implementing and continuing standard treatment. The safety, pharmacokinetics, absorbed dose, and efficacy will be evaluated to determine the recommended dose for Phase II clinical trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Targeted alpha therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Treatment group
- interventionNames
- Drug: Targeted alpha therapy
Primary outcomes (2)
- measure
- Treatment-related adverse events as assessed by CTCAE v5.0
- timeFrame
- From the start of iodine restriction to 6 months after administration
- description
- Type, severity, frequency of occurrence and duration of adverse events
- measure
- Dose Limiting Toxicity
- timeFrame
- within 4 weeks after administration
- description
- Toxicity is defined as one or more of the following items for which a causal relationship with the investigational drug cannot be ruled out. 1. Grade 3 \* hematological toxicity that lasts for 7 days or more 2. Hematological toxicity of Grade 4 \* or higher regardless of duration 3. Febrile neutropenia regardless of duration 4. Thrombocytopenia with bleeding tendency or requiring platelet transfusion 5. Anemia requiring red blood cell transfusion 6. Neutropenia with infection 7. Non-hematological toxicity of Grade 3 \* or higher that does not improve with symptomatic treatment and lasts for 7 days or longer. However, the following are excluded. * Abnormal laboratory test values that are not clinically significant * Toxicity that can be controlled to Grade 2 \* or less with maximum supportive care * Due to exacerbation of the underlying disease (\*: Grade specified in CTCAE v.5.0J COG version)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with differentiated thyroid cancer (papillary cancer, follicular cancer) after total thyroidectomy who meet the following conditions (1) resistance to standard treatment or (2) difficulty in continuing standard treatment (1) Patients who are refractory to standard treatment such as 131I-NaI treatment Insufficient therapeutic effect after 3 or more 131I-NaI treatments. 131I-NaI treatment resistance and difficulty in performing or continuing tyrosine kinase inhibitor (TKI) treatment (2) Patients who have difficulty continuing standard treatment such as 131I-NaI treatment Ablation for residual thyroid or 131I-NaI treatment for relapsed / metastatic lesions has been performed, but relapsed / metastatic lesions were observed at the time of participation in this study, and 131I-NaI is the standard treatment. If it is difficult to continue treatment or if local radiation therapy (including addition) is not indicated (if it is not 131I-NaI treatment resistant, TKI treatment is not indicated). 2. Patients aged 18 years or older at the time of consent acquisition 3. Patients with stable general condition with PS (Performance status) of 0 to 2 in ECOG (Eastern Cooperative Oncology Group) 4. Patients who can be expected to survive for 6 months or more, judging from clinical symptoms and medical examination findings 5. Patients with no or controlled brain metastases with symptoms 6. Patients with no clinically significant abnormal findings in electrocardiogram, respiratory rate, and blood oxygen saturation within 30 days before registration 7. Patients whose laboratory values within 30days before the enrollment are within the range specified in the protocol 8. Patients who thoroughly listened to the explanation of the clinical trial, agreed to the examination, visit during the observation period and follow-up survey, contraception during the clinical trial period, etc. according to the clinical trial protocol, and signed the consent document. Exclusion Criteria: 1. Patients who need fertility preservation 2. Pregnant or potentially pregnant women, lactating patients 3. Patients with active double cancer (simultaneous double cancer and ectopic double cancer with a disease-free period of 5 years or less) 4. Patients who received other investigational or unapproved drugs within 5 weeks prior to enrollment 5. Patients who received chemotherapy, immunotherapy or radiation therapy within 8 weeks prior to enrollment in this study 6. Patients with uncontrollable active infections 7. HBsAg positive, HCV antibody positive or HIV antibody positive patients 8. Patients with mental illness or psychiatric symptoms who are judged to be difficult to participate in clinical trials 9. Other patients who are judged to be inappropriate by the investigator, etc.
References
Publications (0)
Data not yet available
No reference posted for this study.